Trial · NCT07906340
Magnesium Kinetics During Citrate-Anticoagulated CRRT
NCT07906340, Not yet recruiting, Region Skane
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Magnesium Kinetics During Citrate-Anticoagulated CRRT. Trials, record NCT07906340. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906340
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Magnesium Kinetics During Citrate-Anticoagulated CRRT
- NCT number
- NCT07906340
- Status
- Not yet recruiting
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Region Skane
- Conditions
- Continuous Renal Replacement Therapy (CRRT), Magnesium
- Interventions
- Serial blood and dialysis circuit fluid sampling
- First posted
- 2026-10-30
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in systemic total magnesium concentration | Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation. | Changes in systemic total magnesium concentration (mmol/L), measured using conventional clinical laboratory methods, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation. |
| Primary | Changes in systemic ionized magnesium concentration | Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation. | Changes in systemic ionized magnesium concentration (mmol/L), measured using ion-selective electrode technology, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation. |
| Primary | Citrate-associated changes in magnesium ionization | At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation. | Changes in the ionized magnesium fraction (ionized magnesium/total magnesium) between systemic and pre-filter blood will be assessed following administration of citrate-containing predilution fluid, accounting for dilution. Ionized magnesium will be measured using ion-selective electrode technology and total magnesium using conventional clinical laboratory methods. |
| Primary | Magnesium flux across the extracorporeal filter | At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation. | Magnesium flux across the extracorporeal filter (mmol/h) will be calculated using total and ionized magnesium concentrations in pre-filter and post-filter blood and effluent fluid, accounting for blood flow rates, treatment fluid flow rates and fluid composition. Ionized magnesium will be measured using ion-selective electrode technology and total magnesium using conventional clinical laboratory methods. |
| Primary | Net magnesium loss attributable to CRRT | At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation. | Net magnesium loss attributable to CRRT (mmol/h) will be calculated from magnesium removal in the effluent, accounting for magnesium supplied through dialysate and post-filter replacement fluids. Calculations will use the actual treatment fluid composition and flow rates at each sampling time. Ionized magnesium will be measured using ion-selective electrode technology and total magnesium using conventional clinical laboratory methods. |
| Secondary | Changes in systemic total calcium concentration | Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation. | Changes in systemic total calcium concentration (mmol/L), measured using conventional clinical laboratory methods, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation. |
| Secondary | Changes in systemic ionized calcium concentration | Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation. | Changes in systemic ionized calcium concentration (mmol/L), measured using ion-selective electrode technology, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation. |
| Secondary | Calcium flux across the extracorporeal filter | At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation. | Calcium flux across the extracorporeal filter (mmol/h) will be calculated using total and ionized calcium concentrations in pre-filter and post-filter blood and effluent fluid, accounting for blood flow rates, treatment fluid flow rates and fluid composition. Ionized calcium will be measured using ion-selective electrode technology and total calcium using conventional clinical laboratory methods. |
| Secondary | Net calcium loss attributable to CRRT | At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation. | Net calcium loss attributable to CRRT (mmol/h) will be calculated from calcium removal in the effluent, accounting for calcium supplied through dialysate and post-filter replacement fluids. Calculations will use the actual treatment fluid composition and flow rates at each sampling time. Ionized calcium will be measured using ion-selective electrode technology and total calcium using conventional clinical laboratory methods. |
| Secondary | Changes in systemic phosphate concentration | Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation. | Changes in systemic phosphate concentration (mmol/L), measured using conventional clinical laboratory methods, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906340
GET https://conductscience.org/api/trials/v1/NCT07906340/registered